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We present a case of a 19-year old male with uncommon initial clinical cystic ﬁbrosis (CF) presentation and a rare CFTR genotype,
homozygote for c.1393-1GNA mutation (legacy name 1525-1GNA).
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Case report
The boy of Caucasian origin (Serbian) was born to healthy
non-consanguineous parents at term following a healthy
pregnancy with neonatal jaundice and no perinatal complica-
tions. Birth weight was 3.1 kg and length 51 cm. The child was
exclusively breastfed for 4 months, after which he received
complementary foods and continued breastfeeding until he was
2 years old. He did well in the neonatal period and did not
manifest any respiratory or other problems, except for the
excessive fat in stool after 2 years of age. Two older children of
the same parents (both male) died at breastfeeding age, one due
to pneumonia (8 months old) and the other of sudden infant
death syndrome (9 months old). It is probable that they suffered
from CF, but no molecular diagnostics was performed in these
cases. The boy's parents and grandparents are of Serbian origin.
The patient was hospitalized for the first time due to liver
steatosis confirmed by ultrasonography at the age of 7. On⁎ Corresponding author at: Institute of Molecular Genetics and Genetic
Engineering, Vojvode Stepe 444a, PO Box 23, 11010 Belgrade, Serbia. Tel.:
+381 11 3976658; fax: +381 11 3975808.
E-mail address: aleksni@imgge.bg.ac.rs (A. Nikolic).
1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.07.001admission a height of 115.5 cm and a body weight of 20.5 kg
were reported. Physical examination findings were normal.
Laboratory analyses revealed low cholesterol (2.97 mmol/L) and
triglyceride (0.41 mmol/L) serum levels. Values for liver function
tests, blood gas analyses and standard blood test were within
the normal range, as well as levels of total protein, albumins,
alkaline phosphatase, urea, glycemia, sodium, potassium,
chloride, iron, calcium and phosphorus. Chest X-ray showed
expanded interstitium, with no signs of hyperinflation. Findings
on otorhinolaryngological examination were normal, as well as on
echocardiogram and electrocardiogram. Pathohistological exam-
ination showed no abnormalities in the duodenal epithelium.
Ultrasonographical examination indicated liver steatosis, but no
evidence of hepatomegaly. The CF was suspected due to the liver
steatosis, which represents a rather uncommon way to diagnose
CF. Elevated sweat test of 110 mmol/L was diagnostic of CF
(normal values b40 mmol/L, borderline values 40–60 mmol/L).
Routine genetic analysis did not detect presence of any of themost
common CFTR mutations. In order to screen the CFTR gene for
other mutations, all 27 exons (along with their flanking regions)
were analyzed by PCR and direct DNA sequencing. Splicing
mutation c.1393-1GNA on a haplotype background TG10-T9 was
detected in the homozygous state, and both parents were
confirmed to be mutation carriers. Upon diagnosis, adequate diet
and therapeutic measures were introduced: pancreatic enzymeby Elsevier B.V. All rights reserved.
112 A. Nikolic et al. / Journal of Cystic Fibrosis 13 (214) 111–113replacement therapy (Creon) with every meal and restriction of
long-chain triglycerides and supplementation of essential fatty
acids, medium-chain triglycerides, liposoluble vitamins (A, D, E)
and sodium chloride. The patient was apparently healthy until the
age of 12.
At the age of 12 mild chronic bronchitis (without pneumonia
or sinusitis) and cholestasis manifested. Ultrasonographical
examination of the abdomen indicated persistent liver steatosis
without hepatomegaly. Except for lower concentration of serum
triglycerides (0.7 mmol/L), other laboratory analyses, including
cholesterol levels, were within the reference range. The patient
has also developed signs of mild cholestasis, with elevated levels
of gamma glutamyl transpeptidase (GGT 83 U/L; normal value
b50 U/L) and alkaline phosphatase (ALP 1402 U/L; normal
value b1200 U/L). Laboratory findings were also indicative of
hepatocyte lysis, with elevated alanine aminotransferase (ALT
107 U/L; normal value b50 U/L) and aspartate aminotransferase
(AST 72 U/L, normal value b46 U/L). Other laboratory findings
(including bilirubin, PT, PTT and creatine phosphokinase) were
within reference range.
At the age of 17 the patient had no subjective health problems,
but on physical examination signs of mild obstructive bronchitis
and emphysema were found and clubbing fingers were observed.
Chest X-ray showed expanded interstitium with signs of mild
emphysema, as well as signs of hyperinflation and fibrosis
(Fig. 1). Chest CT scan showed apical and posterior condensation
of the right upper lobe. Tubular and cystic bronchiectases with
obliteration and inflammation of bronchioles were observed,
as well as dorsal bilateral pleural adhesions of upper lobes.
Spirometry showed significant decrease of airflow (FVC 35%
and FEV1 40%). The number of leukocytes in induced sputum
showed 5% of eosinophils, 48% of neutrophils, 12% of
lymphocytes, 10% of monocytes and 25% of macrophages.
Laboratory findings were within normal values, except for mild
cholestasis with non-progressive course.Fig. 1. Chest X-ray showing expanded interstitium with signs of mild
emphysema, hyperinflation and fibrosis.At the age of 19 the patient was referred to the pulmonary
department due to repeated respiratory exacerbations and frequent
obstructions with cough and morning sputum production. After
pulmonary reevaluation the following therapy was administered:
inhaled gentamicin, ibuprofen, pulmosine and postural drainage,
with antibiotic therapy for Haemophilus (15 days, IV) and switch
antibiotic therapy (15 days, per os). After exacerbation was treated
pulmonary findings returned to normal (FEV1 55% and FVC
53%), the bronchodilator test was positive and the patient remains
on a fixed combination of inhaled corticosteroids and beta 2
agonists with aminoglycoside inhalations.
2. Discussion
With the exception of the most common mutation
c.1521_1523delCTT (legacy name F508del), the vast majority of
CFTR mutations are rare or restricted to certain populations and
their influence on clinical phenotype is understudied [1]. Splicing
mutation c.1393-1GNAwas first described in 1993 in a CF patient
of Indo-Iranian origin with severe gastrointestinal and pulmonary
disease [2]. To date, this mutation has been found almost
exclusively in patients of Asian origin in compound heterozygotes
with a severe form of CF [3–5].
Molecular characterization has shown that the transcript product
of c.1393-1A allele results from splicing between the intron 9
donor and the intron 10 acceptor [5]. Since exon 10 codes for a
large proportion of the first nucleotide binding domain (NBD1) of
the CFTR protein, essential for the function of the protein, its
absence can cause substantial changes in protein structure and such
mutants show major defects in channel opening. Therefore, the
consequences of the c.1393-1GNA mutation resemble those of the
c.1521_1523delCTT mutation, also located in NBD1.
The influence of the mutation c.1393-1GNA on CF clinical
phenotype was studied only in compound heterozygotes with
the mutation c.1521_1523delCTT [5]. In such cases, functional
analysis showed that CFTR function is defective in native
tissues from c.1393-1GNA/c.1521_1523delCTT patients. In
compound heterozygotes described so far in the literature the
CF clinical presentation was typical, with respiratory problems
and pancreatic insufficiency, and they were diagnosed until
the age of 5 [1,3]. The homozygous patient described here
differs in most aspects of clinical presentation from the
compound heterozygotes: the main symptom at diagnosis was
liver disease, pancreatic insufficiency was mild and well
controlled, and respiratory problems were occasional during
the first 18 years of life. Exocrine pancreatic insufficiency was
compensated by breastfeeding for two years after birth and
consistent treatment, which explain the patient's satisfactory
growth and development until initial admission. Prior to puberty,
which was not delayed, he has gradually developed respiratory
problems and cholestasis. The patient was not on preventive
pulmonary therapy until 19 years of age due to the fact that
respiratory problems were occasional and spirometry results were
within normal range.
An uncommon initial clinical presentation and disease
course in this rare CFTR genotype may contribute to the
understanding of the influence the mutation c.1393-1GNA has
113A. Nikolic et al. / Journal of Cystic Fibrosis 13 (2014) 111–113on CF clinical phenotype. No homozygotes for this mutation
have been reported so far and functional analyses performed on
c.1393-1GNA mutation did not include this mutation in a
homozygous state. This report indicates that there may be a
phenotype difference between homozygotes and compound
heterozygotes for this mutation. Further clinical and functional
studies are needed to resolve this question.Acknowledgments
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